Gensia Sicor Inc. Changes Its Name to SICOR Inc. To

Reflect Its Expanding Strategic Direction IRVINE, Calif. (PROTEXT) - Gensia Sicor Inc. (Nasdaq: GNSA)today announced that it has officially changed its name to SICORInc. following shareholder approval at the Company's AnnualStockholder Meeting, which took place yesterday at the Companyheadquarters in Irvine, California. In addition to the namechange, the Company has also changed its trading ticker symbol toSCRI, under which SICOR will begin trading at the opening of themarket on Friday, June 18, 1999. In addition to the name change, SICOR stockholders alsoapproved the re-election of Donald E. Panoz, Michael D. Cannonand Gianpaolo Colla as Class I Directors, the addition of 100,000share to the SICOR Employee Stock Purchase Plan, the addition of1.6 million shares to SICOR's Long-term Incentive Plan, and theratification of Ernst & Young as the Company's independentauditors. SICOR also announced that it has completed its previouslyannounced private placement of approximately $35 million incommon stock and warrants with private investors. SICOR intendsto use the proceeds to retire short-term and long-term debt andfor general corporate purposes. SICOR Inc. is a vertically integrated specialty pharmaceuticalcompany with proven expertise in the development, manufacturingand marketing of multi-source injectable pharmaceuticals. With astrategy of combining both the production of activepharmaceutical ingredients utilizing synthesis or fermentationand state of the art manufacturing facilities, SICOR's primaryfocus is on the worldwide injectable pharmaceutical market, whichcurrently includes oncology, anesthesiology, cardiology and othertherapeutic areas. SICOR operates several manufacturingfacilities in Europe, Mexico and the U.S.A., while maintainingthe corporate headquarters in Irvine, California. This press release contains forward looking statements thatare subject to risks and uncertainties that could cause actualresults to differ materially from those set forth in the forwardlooking statements, including whether the Company will besuccessful in expanding its current role in the pharmaceuticalindustry, whether the Company will be a leading producer ofinjectable pharmaceuticals and those matters set forth in therisk factors section of SICOR's filings on Forms 10-K and 10-Qwith the Securities and Exchange Commission. These forwardlooking statements represent the Company's judgment as of thedate of this press release. The Company disclaims any intent orobligation to update these forward looking statements. For more information on the Company, visit SICOR's web site atwww.gensiasicor.com. News releases are also available at nocharge through PR Newswire's News On-Call fax service. For a menuof available news releases or to retrieve a specific release madeby SICOR, call 800-758-5804, extension 354050. Please retainthese numbers for future reference. ots Original Text Service:Gensia Sicor Inc. Internet: http://www.newsaktuell.de Contact:Laurie W. Little of SICOR Inc., 949-455-4879; or Carolyn Bass orJim Byers, 415-296-7383, or Patricia Walsh or Mark Owen, 212-850-5600, all of Morgen-Walke Associates, Inc., for SICOR Inc.Company News On-Call: http://www.prnewswire.com/comp/354050.htmlor fax, 800-758-5804, ext. 354050 Web site:http://www.gensiasicor.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT